PubRank

C Garrison Fathman

Author PubWeight™ 79.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003 7.78
2 Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002 6.11
3 The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002 3.09
4 Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2004 2.95
5 The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002 2.93
6 Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004 2.76
7 GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 2003 2.18
8 Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012 2.08
9 Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 2004 1.89
10 Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation 2005 1.82
11 A model for harmonizing flow cytometry in clinical trials. Nat Immunol 2010 1.70
12 Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 2009 1.65
13 Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nat Immunol 2003 1.57
14 CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J Allergy Clin Immunol 2002 1.56
15 Pillars article: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000. 100: 655-669. J Immunol 2015 1.44
16 Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med 2006 1.39
17 The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J Immunol 2004 1.36
18 Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice. Clin Immunol 2008 1.33
19 Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol 2008 1.29
20 A novel E3 ubiquitin ligase substrate screen identifies Rho guanine dissociation inhibitor as a substrate of gene related to anergy in lymphocytes. J Immunol 2006 1.18
21 L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood 2005 1.18
22 New tools for classification and monitoring of autoimmune diseases. Nat Rev Rheumatol 2012 1.13
23 Cutting edge: The transmembrane E3 ligase GRAIL ubiquitinates the costimulatory molecule CD40 ligand during the induction of T cell anergy. J Immunol 2008 1.13
24 Naive and memory T cells induce different types of graft-versus-host disease. J Immunol 2007 1.12
25 GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem 2007 1.11
26 Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol 2012 1.10
27 Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells. Blood 2009 1.10
28 The single subunit transmembrane E3 ligase gene related to anergy in lymphocytes (GRAIL) captures and then ubiquitinates transmembrane proteins across the cell membrane. J Biol Chem 2008 1.09
29 Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins. J Biol Chem 2012 1.07
30 Multimodality imaging of T-cell hybridoma trafficking in collagen-induced arthritic mice: image-based estimation of the number of cells accumulating in mouse paws. J Biomed Opt 2007 0.99
31 Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J Immunol 2004 0.97
32 Naive CD4 t cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression. J Immunol 2009 0.95
33 The transmembrane E3 ligase GRAIL ubiquitinates and degrades CD83 on CD4 T cells. J Immunol 2009 0.94
34 Reduced DEAF1 function during type 1 diabetes inhibits translation in lymph node stromal cells by suppressing Eif4g3. J Mol Cell Biol 2012 0.89
35 GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness. FEBS J 2010 0.89
36 Costimulatory signals controlling regulatory T cells. Proc Natl Acad Sci U S A 2003 0.89
37 A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. Mol Ther 2010 0.89
38 Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin Immunol 2002 0.88
39 Treatment of autoimmune disease by adoptive cellular gene therapy. Ann N Y Acad Sci 2003 0.88
40 It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes 2014 0.85
41 Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis. Immunol Res 2014 0.82
42 Targeted gene therapy: frontiers in the development of 'smart drugs'. Trends Biotechnol 2004 0.82
43 Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis. Clin Immunol 2011 0.82
44 Diminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes. Diabetes 2013 0.81
45 Adoptive cellular gene therapy of autoimmune disease. Autoimmun Rev 2002 0.80
46 T-cell anergy: from phenotype to genotype and back. Immunol Res 2003 0.79
47 Targeted gene therapy of autoimmune diseases: advances and prospects. Expert Rev Clin Immunol 2005 0.79
48 Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease? Nat Clin Pract Rheumatol 2006 0.77
49 High cell surface expression of CD4 allows distinction of CD4(+)CD25(+) antigen-specific effector T cells from CD4(+)CD25(+) regulatory T cells in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 2007 0.77
50 Short polymers of arginine rapidly translocate into vascular cells: effects on nitric oxide synthesis. Circ J 2002 0.77
51 T cell anergy: where it's LAT. Immunity 2006 0.76
52 CYLD: deubiquitination-induced TCR signaling. Nat Immunol 2006 0.75
53 Scratching the (T cell) surface. Genome Biol 2003 0.75
54 The potential for gene therapy in the treatment of autoimmune disease. Clin Immunol 2002 0.75
55 Gene therapy for type 1 diabetes: a novel approach for targeted treatment of autoimmunity. J Clin Invest 2004 0.75
56 Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Autoimmun Rev 2005 0.75
57 30. Defining the spectrum of clinical immunology. J Allergy Clin Immunol 2003 0.75
58 Immunomodulatory vaccination in autoimmune disease. Endocrinol Metab Clin North Am 2002 0.75